Nephrotic proteinuria associated with high‐dose pamidronate in multiple myeloma
- 30 October 2002
- journal article
- case report
- Published by Wiley in British Journal of Haematology
- Vol. 119 (2) , 496-499
- https://doi.org/10.1046/j.1365-2141.2002.03826.x
Abstract
Summary. Five patients receiving increased dose or frequency of pamidronate beyond the recommended dose (90 mg/monthly) exhibited nephrotic proteinuria (range 3·96–24 g/24 h). On dose reduction or discontinuation, three of these patients showed decreased proteinuria to normal levels (< 1 g/24 h), and proteinuria decreased to 4·5 g/24 h from a peak of 24 g/24 h in one patient. One patient on haemodialysis (hence not evaluable) had proteinuria of 2 g/24 h and elevated creatinine levels. One other patient continued to show elevated creatinine levels (272·8 µmol/l). Renal biopsies obtained in two patients revealed focal segmental glomerulosclerosis.Keywords
This publication has 10 references indexed in Scilit:
- Collapsing Focal Segmental Glomerulosclerosis Following Treatment with High-Dose PamidronateJournal of the American Society of Nephrology, 2001
- Protein Geranylgeranylation Is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI-298Journal of Bone and Mineral Research, 2000
- Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myelomaBlood, 2000
- Alendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate SynthaseArchives of Biochemistry and Biophysics, 2000
- Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL-6 and MMP-1 by the Tumoral EnvironmentJournal of Bone and Mineral Research, 1999
- Nitrogen-Containing Bisphosphonates Inhibit Isopentenyl Pyrophosphate Isomerase/Farnesyl Pyrophosphate Synthase Activity with Relative Potencies Corresponding to Their Antiresorptive Potenciesin Vitroandin VivoBiochemical and Biophysical Research Communications, 1999
- Anti‐myeloma activity of pamidronate in vivoBritish Journal of Haematology, 1998
- Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.Journal of Clinical Oncology, 1998
- Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activityBritish Journal of Haematology, 1997
- Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD), in rats and miceToxicology, 1990